Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, ∼4 years of intensive versus standard glycemic control in participants with type 2 diabetes and other cardiovascular risk factors had a neutral effect on the composite cardiovascular outcome, increased cardiovascular and total mortality, and reduced nonfatal myocardial infarction. Effects of the intervention during prolonged follow-up were analyzed. RESEARCH DESIGN AND METHODS: All surviving ACCORD participants were invited to participate in the ACCORD Follow-on (ACCORDION) study, during which participants were treated according to their health care provider’s judgment. Cardiovascular and other health-related outcomes were prospectively collected and analyzed using an intention-to-treat approach according to the group to which participants were originally allocated. RESULTS: A total of 8,601 people, representing 98% of those who did not suffer a primary outcome or death during the ACCORD trial, were monitored for a median of 8.8 years and a mean of 7.7 years from randomization. Intensive glucose lowering for a mean of 3.7 years had a neutral long-term effect on the primary composite outcome (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death), death from any cause, and an expanded composite outcome that included all-cause death. Moreover, the risk of cardiovascular mortality noted during the active phase (hazard ratio 1.49; 95% CI 1.19, 1.87; P < 0.0001) decreased (HR 1.20; 95% CI 1.03, 1.39; P = 0.02). CONCLUSIONS: In high-risk people with type 2 diabetes monitored for 9 years, a mean of 3.7 years of intensive glycemic control had a neutral effect on death and nonfatal cardiovascular events but increased cardiovascular-related death.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the epidemiological follow-up of ACCORD in the Action to Control Cardiovascular Risk in Diabetes Follow-On Study (ACCORDION), the excess increase in total mortality that was seen during 3.5 years of intensive treatment was reduced by returning to conventional management, and therefore there was no difference in total mortality after a total of 9 years of follow-up (62).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [62]
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“A meta-analysis of the odds ratios for death from ACCORDION and these other three studies using a fixed-effects variance estimate (27) with heterogeneity assessed using the I(2) statistic (28) (Supplementary Table 3) yields an overall mortality odds ratio of 0.”
MethodQuantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“A meta-analysis of the odds ratios for death from ACCORDION and these other three studies using a fixed-effects variance estimate (27) with heterogeneity assessed using the I(2) statistic (28) (Supplementary Table 3) yields an overall mortality odds ratio of 0.”
MethodTurner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“9% reduced the 18-year incidence of myocardial infarction by 15% and death by 13% in people with newly diagnosed type 2 diabetes (24).”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Self-citationGlucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Cited by
Items 101–193 of 193
Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus
Fujihara, K., & Sone, H. (2018) · Annals of Vascular Diseases · doi:10.3400/avd.ra.17-00109 · Cited by 10
Sirtuin 1 as the mechanism of action of agents used in the diabetes mellitus pharmacotherapy
Stelmaszyk, A., Mikołajczak, P. Ł., & Dworacka, M. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174289 · Cited by 10
Makam, S., Stein, L. K., & Dhamoon, M. S. (2024) · Stroke · doi:10.1161/strokeaha.124.049178 · Cited by 8
“19 There are several potential mechanisms by which hypoglycemia can trigger a stroke.”
Zhou, Z., Huang, Y., Zhuang, X., Guo, Y., Xie, P., Xiong, Z., Liu, M., Zhang, W., Zhong, J., Li, Y., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.034626 · Cited by 11
Yang, T., Fu, P., Chen, J., Fu, X., Xu, Z., Liu, X., & Niu, T. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1947219 · Cited by 14
Steno-2 — a small study with a big heart
BAJAJ, H. S., & Zinman, B. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.172 · Cited by 7
Are diabetes guidelines truly evidence based?
Bouchonville, M. F., Matani, S., DuBroff, J. J., & DuBroff, R. J. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.02.035 · Cited by 8
Tsujimoto, T., & Kajio, H. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13886 · Cited by 6
Goldman, M. P., Corriere, M. A., Craven, T. E., Davis, R. P., Sheehan, M. K., Hurie, J., Velazquez, G., Williams, T. K., Chang, K., & Edwards, M. S. (2020) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2020.10.022 · Cited by 7
Lack of Glycemic Legacy Effects in the Veterans Affairs Diabetes Trial
Lipska, K. J., & Laiteerapong, N. (2019) · New England Journal of Medicine · doi:10.1056/nejme1905495 · Cited by 9
Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes
Guthrie, R. M. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1430446 · Cited by 6
Jung, H. H., & Lee, S. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13892 · Cited by 6
Feng, L., Liu, T., Yang, Y., Xiao, W., Shi, J., Mei, X., Tian, S., Liu, X., Huang, H., & Bai, Y. (2019) · RSC Advances · doi:10.1039/c9ra00705a · Cited by 6
Use of the Burden of Diabetes Mellitus Score for Cardiovascular Disease Risk Assessment
Farjo, P. D., Barghouthi, N., Chima, N. R., Desai, A., Fang, W., Giordano, J., & Bianco, C. M. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.03.027 · Cited by 6
MacIsaac, R. J. (2021) · Future Cardiology · doi:10.2217/fca-2020-0210 · Cited by 8
Chan, J. C. N., Deerochanawong, C., Khunti, K., Hassanein, M. M., & Mohan, V. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113173 · Cited by 9
Indarto, D., Rochmah, D. N., Wiboworini, B., Pratama, Y. M., & Wibowo, Y. C. (2022) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_704_20 · Cited by 7
Aldafas, R., Crabtree, T. S. J., Vinogradova, Y., Gordon, J. P., & IDRIS, I. R. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2166489 · Cited by 7
“These results are consistent with many previous meta-analyses [27–29] and clinical trials [32,33].”
BackgroundResultCoke, L. A., DEEDWANIA, P. C., Hinnen, D., Magwire, M., & Miller, N. H. (2022) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000661 · Cited by 6
Cardiovascular outcome trials in type 2 diabetes: A nurse practitioner perspective
Kruger, D. F. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000126 · Cited by 4
“…with once-weekly GLP-1RAs, which have the potential for greater acceptance and adherence by patients in clinical practice, compared with once-daily treatments (Amblee, 2016; Qiao, Ouwens, Grandy, Johnsson, & Kostev, 2016), as discussed in more details earlier in the supplement (Hinnen, 2018).”
BackgroundZhou, H., Huang, Y., Xie, P., Zhang, S., Liu, M., Xiong, Z., Huang, R., Xu, X., Li, M., Zhou, Z., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.035788 · Cited by 5
Zhang, Y., Dai, L., Wang, M., Zhong, X., Liu, X., Zhang, K., Luo, L., Wang, L., Dong, W., Váczy, A., et al. (2025) · Diabetes · doi:10.2337/db25-0077 · Cited by 5
Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms
BAJAJ, H. S., & Zinman, B. (2018) · Physiology · doi:10.1152/physiol.00004.2018 · Cited by 7
Investigation of Glucose Sensor by using Plasmonic MIM Waveguide Based M
Singh, L., Agrawal, N., & Saha, C. P. (2021) · IEEE MTT-S International Microwave and RF Conference (IMaRC) · doi:10.1109/imarc49196.2021.9714533 · Cited by 4
Kloecker, D. E., Davies, M. J., Pitocco, D., Khunti, K., & Zaccardi, F. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3634 · Cited by 4
United States Pooled Cohort Cardiovascular Disease Risk Scores in Adults With Diabetes Mellitus
Zhao, Y., D’Agostino, R. B., Malik, S., Watson, K. E., Bertoni, A. G., Budoff, M. J., Cain, L., Correa, A., Folsom, A. R., Jacobs, D. R., et al. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101448 · Cited by 7
Joladarashi, D., Zhu, Y., Willman, M., Nash, K. R., Cimini, M., Thandavarayan, R. A., Youker, K. A., Song, X., Ren, D., Li, J., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.798091 · Cited by 4
RetractedZhu, L., Bell, K., & Hayen, A. D. (2019) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.05.010 · Cited by 6
Vos, R. C., den Ouden, H., Daamen, L. A., Bilo, H. J. G., Denig, P., & Rutten, G. E. H. M. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000949 · Cited by 4
Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 5
Empagliflozin reduces cardiovascular events and mortality in type 2 diabetes
Guthrie, R. M. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1174566 · Cited by 3
Cardiovascular risk factors and incident albuminuria in screen‐detected type 2 diabetes
Webb, D. R., Zaccardi, F., Davies, M. J., Griffin, S. J., Wareham, N. J., Simmons, R. K., Rutten, G. E. H. M., Sandbæk, A., Lauritzen, T., Borch‐Johnsen, K., et al. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2877 · Cited by 5
Kato, Y., Iwata, A., Zhang, B., Miura, S.-I., Imaizumi, S., Kuwano, T., Ike, A., Sugihara, M., Nishikawa, H., Yasunaga, S., et al. (2017) · IJC Metabolic & Endocrine · doi:10.1016/j.ijcme.2017.06.005 · Cited by 4
Significantly Increased Risk of All-Cause Mortality Among Type 2 Diabetes Patients Living Alone
Fu, L., Zhou, Y., Sun, J., Xing, Z., Wang, Y., & Tai, S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.782751 · Cited by 5
“Follow-up continued for the remaining participants in the ACCORDION trial, with a total follow-up period of 8.8 years.”
MethodInfluentialShao, H., Guo, J. S., Laiteerapong, N., Tang, S., Fonseca, V. A., Shi, L., & Zhang, P. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2129234 · Cited by 3
Diabetes and Cerebrovascular Disease
Lioutas, V., & Palaiodimou, L. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_18 · Cited by 3
P-wave axis is associated with all-cause mortality in diabetes: The ACCORD trial
Ehrhardt-Humbert, L. C., Upadhya, B., Bhave, P. D., Soliman, E. Z., Beaty, E., Yeboah, J., & Singleton, M. J. (2020) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2020.04.023 · Cited by 4
Tsujimoto, T., & Kajio, H. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13737 · Cited by 3
Understanding insulin dose deviations in people with type 2 diabetes receiving telemonitoring
Nørlev, J. T. D., Kronborg, T., Jensen, M. H., Vestergaard, P., & Hangaard, S. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.10.001 · Cited by 2
Insulin Treatment of Diabetes Mellitus-Tight vs. Conventional Control
Emanuele, N., & Reaven, P. D. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_34 · Cited by 2
Sadeghi, M., Teimouri-Jervekani, Z., Roohafza, H., Talaei, M., Paknahad, M. H., Dianatkhah, M., Boshtam, M., & Sarrafzadegan, N. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998304318240731051957 · Cited by 2
Handford, C., Stirling-Barros, L., Ganji‐Arjenaki, M., Mahmod, M., Nazarzadeh, M., & Wamil, M. (2025) · Biomedicines · doi:10.3390/biomedicines13092080 · Cited by 3
Fuentes, B., Amaro, S., de Leciñana, M. A., Arenillas, J. F., Martín, Ó. A., Castellanos, M., Freijo, M., García-Pastor, Gomis, M., Choco, M. G., et al. (2021) · Neurología (English Edition) · doi:10.1016/j.nrleng.2020.04.022 · Cited by 11
Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Pietraszek, A. (2020) · Current Drug Safety · doi:10.2174/1574886315666200902154736 · Cited by 2
Wang, N., Zoungas, S., & Chalmers, J. P. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104160 · Cited by 3
Treat‐Jacobson, D. (2019) · Journal of Vascular Nursing · doi:10.1016/j.jvn.2019.12.002 · Cited by 2
Serum Magnesium Level Change in Type 2 Diabetic Patients with Cardiovascular Complications
ELGAZZAR, M. S. E. T. E. M., & AMAL SAID ALBENDARY, M. D. ;. Y. M. A. (2019) · The Medical Journal of Cairo University/The Medical Journal of Cairo University · doi:10.21608/mjcu.2019.59517 · Cited by 1
Achievement of ABC Goals in Type 2 Diabetes in Real-life
Chandalia, H. B., Jain, J. D., & Chandalia, S. H. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0730 · Cited by 1
“17,18 Hypoglycemia has been identified as injurious to cardiovascular system 19 hence exploration of treatment modalities causing a very low incidence of hypoglycemia is considered desirable.”
The Timeline of the Association Between Diabetes and Cardiovascular Diseases: A Narrative Review
Luca, S. A., Bungau, R. M., Lazăr, S., Herascu, A., Gaiţă, L., Avram, V. F., & Timar, B. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196877 · Cited by 1
“The ACCORDION study, a follow-up to the ACCORD trial, confirmed the lack of long-term CV benefits following the intensive glucose control strategy [43].”
Wang, Y., Meng, X., Zhang, X., Li, M., Wang, T., Zhao, Z., Lu, J., Xu, M., Zheng, J., Wang, W., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70498 · Cited by 1
Alam, A. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_11_26 · Cited by 1
Metabolic memory failure and the reprogramming of atherosclerosis in diabetes
Devi, M., Sukumaran, E. S., Harikrishnan, N., Pavithra, N., & Shakthi, L. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100703 · Cited by 1
Goyal, M. K., Hatwal, J., Desai, R., Sehgal, T., & Batta, A. (2026) · World Journal of Diabetes · doi:10.4239/wjd.115820 · Cited by 2
Is diabetes still a state of premature cardiovascular death?
Fisher, M. (2016) · Practical Diabetes · doi:10.1002/pdi.2057 · Cited by 1
Jermendy, G. (2018) · Orvosi Hetilap · doi:10.1556/650.2018.31041 · Cited by 1
Facteurs de risque et maladies chroniques : le diabète en exemple
Schlienger, J.-L., Monnier, L., Essekkat, N., Azrak, A. E., Raji, F., & Rochd, D. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30019-7 · Cited by 4
Ferraro, R., NASS, C. M., Dudum, R., Blumenthal, R. S., & Sarkar, S. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.02.050 · Cited by 1
Rizvi, A. A. (2017) · EMJ Diabetes · doi:10.33590/emjdiabet/10312697 · Cited by 28
Alicic, R. Z., & Tuttle, K. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00037-8 · Cited by 1
Skoczyńska, A., Wawrzynowicz‐Syczewska, M., Barlik-Rysa, M., Danik, A., Różański, J., Filipiak, K. J., & Cybulska, B. (2020) · Folia Cardiologica · doi:10.5603/fc.2020.0001 · Cited by 1
Hypoglycemia and the risk of stroke in patients with type 2 diabetes mellitus in older age groups
Ostroumova, O. D., Starodubova, A. V., Alexey, I. K., De, V. A., Оstroumova, Т. М., & Kiknadze, T. D. (2020) · Medical news of the North Caucasus · doi:10.14300/mnnc.2020.15144 · Cited by 1
“…терапии эпизоды гипогликемии регистрировались чаще, чем в группе стандартной терапии (1,06 и 0,29 эпизодов в неделю соответственно), а вероятность риска не-фатального инсульта была даже несколько ниже в случаях интенсивного контроля глюкозы (различия не были статистически значимыми) [22–24].”
Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 2
Murphy, E., Cooney, M. T., & McEvoy, J. W. (2022) · Contemporary cardiology · doi:10.1007/978-3-031-16594-8_2 · Cited by 1
Geller, N. L., Waclawiw, M. A., & Friedman, L. M. (2016) · Wiley eBooks · doi:10.1002/9781118445112.stat04987.pub2 · Cited by 1
Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?
Tan, S. K., & Cooper, M. E. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2277762 · Cited by 1
Theodoraki, A. (2025) · BMJ · doi:10.1136/bmj.r1726 · Cited by 1
Preventing all the complications of hyperglycaemia: not a straightforward task
McElduff, A. (2016) · The Medical Journal of Australia · doi:10.5694/mja16.00726 · Cited by 1
Diabetes and hypertension: too many guidelines, not enough data
Cryer, M., Baker, W. D. C., Horani, T., & DiPette, D. J. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000102
Langfristige Effekte einer multifaktoriellen Therapie bei Typ-2-Diabetes
Jecht, M. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0156-8
Assessment of putative risk factors in the development of Diabetic Retinopathy in Wales
Chowdhury, S. R. (2016) · ORCA Online Research @Cardiff (Cardiff University)
Diabète de type2 etdyslipidémie
Ziegler, O., & Böhme, P. (2017) · doi:10.1016/b978-2-294-74646-8.00019-5
Why Should be the Strategy of Type 2 Diabetes Treatment Radically Changed
Gmitrov, J. (2017) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.1515/rjdnmd-2017-0032
Fisher, M. (2018) · Wiley eBooks · doi:10.1002/9781119374800.ch39
Glycemic Targets and Prevention of Chronic Complications
Cernea, S., Cahn, A., & Raz, I. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_14-1
Insulin Resistance Modification is a Game Changer for Type 2 Diabetes Treatment Strategy
Gmitrov, J. (2018) · International Journal of Diabetes and Clinical Research · doi:10.23937/2377-3634/1410096
New Trends: Time in Range and the Use of Continuous Glucose Monitoring Devices on Glycemic Control
Souza, K. L. V. D., Rassi, M. M. B., de Sá, D. A. R., Bussuan, R. M., Rodrigues, L. C. D. S., & Arbex, A. K. (2021) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2021.3.1.491 · Cited by 1
Cobo, A. L., Masson, W. M., Lobo, M., Masson, G., & Molinero, G. B. (2021) · Research Square · doi:10.21203/rs.3.rs-664920/v1
Fu, L., Tai, S., Sun, J., Zhang, N., Zhou, Y., Xing, Z., Wang, Y., & Zhou, S. (2021) · Research Square · doi:10.21203/rs.3.rs-960363/v1
Glycemic Targets and Prevention of Chronic Complications
Cernea, S., Cahn, A., & Raz, I. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_14
Segar, M. W., Patel, K. V., Vaduganathan, M., Caughey, M. C., Butler, J., Fonarow, G. C., Grodin, J. L., McGuire, D. K., & Pandey, A. (2020) · doi:10.2337/figshare.12273155
Aronow, W. S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735910698.793566214
Segar, M. W., Patel, K. V., Vaduganathan, M., Caughey, M. C., Butler, J., Fonarow, G. C., Grodin, J. L., McGuire, D. K., & Pandey, A. (2020) · doi:10.2337/figshare.12273155.v2
Control of Blood Glucose and Cardiovascular Risk Profile
Ciardullo, S., & Perseghin, G. (2022) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_28
Paradigm sift of the medical care in diabetes
Okajima, F. (2023) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.19.32
León, J. S. T., Ardila, L. J. P., Santamaria, M. J. C., Quintero, V. Q., Campo, E. R. Z., Corzo, M. J. O., Cantillo, F. A. A., Romero, L. D. J., Medina, R. A. A., Solano, M. J. C., et al. (2024) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v8i1.10179
“…12, 13), el ensayo Acción para Controlar el Riesgo Cardiovascular en la Diabetes (ACCORD) con más de 10 000 pacientes diabéticos tipo 2 de larga evolución (14, 15), o el estudio Action in Diabetes and Vascular Disease Preterax and Diamicron (ADVANCE) en 11140 pacientes diabéticos tipo 2 (16, 17).”
Detection and Treatment of Chronic Complications
Soe, K. K., & Gunasekaran, U. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch05
Global Initiative for Glycolipid Metabolic Health
Guo, J. (2025) · Journal of Holistic Integrative Pharmacy · doi:10.1016/j.jhip.2025.06.001
Tai, S., Fu, L., Zhang, N., Yang, R., Zhou, Y., Xing, Z., Wang, Y., & Zhou, S. (2022) · Figshare · doi:10.6084/m9.figshare.20579619
Tai, S., Fu, L., Zhang, N., Yang, R., Zhou, Y., Xing, Z., Wang, Y., & Zhou, S. (2022) · Figshare · doi:10.6084/m9.figshare.20579616
Kim, T. H., Hwang, Y., Woo, S., Lee, K., Son, Y., Park, S., Kim, H., Shin, J., Cho, Y., Shin, D., et al. (2026) · Medicine · doi:10.1097/md.0000000000047235 · Cited by 1
“[6] Intensive control consistently reduces microvascular outcomes, [7] although the magnitude of benefit depends on clinical context.”
Role of Epac2 in high glucose-mediated cardiac calcium mishandling.
Hayek, M. S. E. (2020) · theses.fr (ABES) · doi:10.70675/c2d7d63fzf026z4bbbz9358z403c1386e2c7
Prato, S. D., Genovese, S., Galeone, C., Mariani, P., Acquaviva, T., Antonutti, M., Anzaldi, M., Bucciarelli, L., Carleo, D., Cesaro, A., et al. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02770-w
Antidiabetic medications and arterial thrombotic risk reduction: a narrative review
Santilli, F., Simeone, P., & Liani, R. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04502-y
Metadata
- Authors
- The ACCORD Study Group
- Corresponding author
- The ACCORD Study Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-01-28
- Volume
- 39
- Issue
- 5
- Pages
- 701-708
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC4839177
- OpenAlex
- W2589131700
- Cited by
- 193
- References
- 35
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 9 · 2023: 16 · 2022: 13 · 2021: 24 · 2020: 27 · 2019: 25 · 2018: 24 · 2017: 18 · 2016: 18
- FWCI
- 28.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (N01-HC-95178, N01-HC-95179, N01-HC-95180, N01-HC-95181, N01-HC-95182, N01-HC-95183, N01-HC-95184, IAA #Y1-HC-9035, IAA#Y1-HC-1010, HHSN268201100027C)
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute on Aging
- National Eye Institute
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- tight glycemic control, type 2 diabetes, cardiovascular outcomes, cardiovascular mortality, nonfatal myocardial infarction, non-fatal stroke, ACCORD trial, long-term follow-up, HbA1c
- MeSH terms
- Aged, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Middle Aged, Prospective Studies, Risk Factors, Incidence, Proportional Hazards Models, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.